CMPI · Checkmate Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $45.82M | $26.72M |
| SG&A | $15.65M | $10.19M |
| Total Operating Expenses | $61.47M | $36.90M |
| D&A | $66.0K | - |
| Operating Income | ($61.47M) | ($36.90M) |
| Interest Expense | - | - |
| Income Tax | - | - |
| Net Income | ($61.41M) | ($36.91M) |
| EPS - Basic | - | - |
| EPS - Diluted | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash & Equivalents | $50.67M | $43.05M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $3.38M | $2.30M |
| Current Assets | $73.96M | $102.10M |
| Total Assets | $78.84M | $133.07M |
| Current Liabilities | $9.38M | $7.88M |
| Long-term Debt | - | - |
| Total Liabilities | $9.38M | $7.88M |
| Stockholders' Equity | $69.46M | $125.20M |
| Retained Earnings | ($201.48M) | ($140.07M) |
Cash Flow
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Operating Cash Flow | ($53.72M) | ($38.11M) |
| Investing Cash Flow | $61.19M | ($83.29M) |
| Financing Cash Flow | $146.0K | $160.27M |
| CapEx | $843.0K | - |
| Free Cash Flow | ($54.56M) | - |
Ratios
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 0.89 | - |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -77.9% | -27.7% |
| Return on equity | -88.4% | -29.5% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 7.89 | 12.97 |
| Quick ratio | 7.89 | 12.97 |
| Cash ratio | 5.40 | 5.47 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.14 | 1.06 |
| Liabilities / Assets | 0.12 | 0.06 |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -66.6% | - |
| Net income growth (YoY) | -66.4% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | - | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -44.5% | - |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Checkmate Pharmaceuticals against the 5 most active filers in the same SIC group.